A pilot study of neoadjuvant combination of anti-pd-1 camrelizumab and vegfr2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

HIGHLIGHTS

• who: Wu-tong Ju from the Study population and trial design This single-centre, open-label phase I trial was performed at the Ninth People`s Hospital, Shanghai Jiao Tong University School of Medicine in Shanghai, ChinaEligible patients were aged, years, had histopathologically confirmed locally advanced OSCC with a clinical stage of III or IVA (American Joint Committee on Cancer, th Edition), and had an Eastern Cooperative Oncology Group performance status of , to, . Patients were enroled between April, and December, . The full eligibility criteria are provided in the trial protocol (Supplementary Note, ). The trial followed the ethical . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.